{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:36:41Z","timestamp":1791247001400,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012443","name":"Maryland Stem Cell Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtct.2025.10.021","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T01:35:46Z","timestamp":1762392946000},"page":"310-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4609","authenticated-orcid":false,"given":"Amy E.","family":"DeZern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-6721","authenticated-orcid":false,"given":"Marianna","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Cavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Pierse","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0275-6931","authenticated-orcid":false,"given":"Kenneth R.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-195X","authenticated-orcid":false,"given":"Philip H.","family":"Imus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina D.","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-3412","authenticated-orcid":false,"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-9653","authenticated-orcid":false,"given":"Alexander","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5911-3873","authenticated-orcid":false,"given":"Cole","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-1164","authenticated-orcid":false,"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtct.2025.10.021_bib0001","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.021_bib0002","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjh.17232","article-title":"Eltrombopag added to immunosuppression for children with treatment-na\u00efve severe aplastic anaemia","volume":"192","author":"Groarke","year":"2021","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.jtct.2025.10.021_bib0003","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.021_bib0004","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/s41409-025-02633-y","article-title":"Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT","volume":"60","author":"Montoro","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.021_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jtct.2025.10.021_bib0006","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1182\/bloodadvances.2024015102","article-title":"Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial","volume":"9","author":"Shimamura","year":"2025","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.jtct.2025.10.021_bib0007","first-page":"3031","article-title":"Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia","volume":"141","author":"DeZern","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.021_bib0008","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","article-title":"Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide","volume":"4","author":"DeZern","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.021_bib0009","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.021_bib0010","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.021_bib0011","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood.V48.1.63.63","article-title":"Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality","volume":"48","author":"Camitta","year":"1976","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.021_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcyt.2024.09.001","article-title":"The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee","volume":"27","author":"Oved","year":"2025","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.021_bib0013","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12185-022-03506-6","article-title":"Allogeneic bone marrow transplantation for aplastic anemia","volume":"119","author":"Storb","year":"2024","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.021_bib0014","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2141.2012.09130.x","article-title":"Success of allogeneic marrow transplantation for children with severe aplastic anaemia","volume":"158","author":"Burroughs","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.021_bib0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjh.13614","volume":"171","author":"Dufour","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.021_bib0016","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjh.13297","article-title":"Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant","volume":"169","author":"Dufour","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.021_bib0017","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3324\/haematol.2023.284022","article-title":"Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia","volume":"109","author":"DeZern","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.021_bib0018","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jtct.2024.09.017","article-title":"Allogeneic hematopoietic cell transplantation for the treatment of severe aplastic anemia: evidence-based guidelines from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Iftikhar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.021_bib0019","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.021_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.1988.tb07597.x","article-title":"Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia","volume":"69","author":"Niederwieser","year":"1988","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.021_bib0021","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2013.01.016","article-title":"Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies","volume":"19","author":"Gladstone","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.10.021_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/asheducation.V2012.1.292.3798310","article-title":"Aplastic anemia: therapeutic updates in immunosuppression and transplantation","volume":"2012","author":"Scheinberg","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2025.10.021_bib0023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/asheducation.V2012.1.223.3798305","article-title":"Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation?","volume":"2012","author":"Bacigalupo","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.021_bib0024","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.hoc.2018.04.001","article-title":"Haploidentical donor bone marrow transplantation for severe aplastic anemia","volume":"32","author":"DeZern","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.021_bib0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.seminhematol.2019.03.004","article-title":"Haploidentical donor transplants for severe aplastic anemia","volume":"56","author":"Bacigalupo","year":"2019","journal-title":"Semin Hematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.021_bib0026","first-page":"45","article-title":"Changing trends in marrow transplantation for aplastic anemia","volume":"10","author":"Storb","year":"1992","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.021_bib0027","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/bmt.2010.213","article-title":"Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia","volume":"46","author":"Dezern","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2025.10.021_bib0028","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V126.23.2031.2031","article-title":"Using haploidentical (haplo) donors and high-dose post-transplant cyclophosphamide (PTCy) for refractory severe aplastic anemia (SAA)","volume":"126","author":"Dezern","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.021_bib0029","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bbmt.2018.09.040","article-title":"Employment, insurance, and financial experiences of patients with chronic graft-versus-host disease in North America","volume":"25","author":"Khera","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.021_bib0030","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bmt.2016.103","article-title":"Financial impact of allogeneic hematopoietic cell transplantation on patients and families over 2 years: results from a multicenter pilot study","volume":"51","author":"Denzen","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"28","key":"10.1016\/j.jtct.2025.10.021_bib0031","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.021_bib0032","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MOH.0b013e32833eaf1b","article-title":"High-dose cyclophosphamide for graft-versus-host disease prevention","volume":"17","author":"Luznik","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.021_bib0033","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1 Suppl","key":"10.1016\/j.jtct.2025.10.021_bib0034","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.bbmt.2012.10.007","article-title":"HCT for nonmalignant disorders","volume":"19","author":"Tisdale","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"10.1016\/j.jtct.2025.10.021_bib0035","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.021_bib0036","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbmt.2016.02.001","article-title":"Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders","volume":"22","author":"Klein","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.021_bib0037","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.bbmt.2014.06.028","article-title":"Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia","volume":"20","author":"Clay","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.021_bib0038","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/bmt.2015.20","article-title":"Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study","volume":"50","author":"Esteves","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.10.021_bib0039","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/asheducation-2013.1.87","article-title":"Management of the refractory aplastic anemia patient: what are the options?","volume":"2013","author":"Marsh","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.021_bib0040","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/bmt.2015.251","article-title":"Unmanipulated haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with paroxysmal nocturnal hemoglobinuria and secondary aplastic anemia","volume":"51","author":"Sarmiento","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.021_bib0041","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/bmt.2012.79","article-title":"A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia","volume":"47","author":"Xu","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.021_bib0042","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3324\/haematol.2019.222562","volume":"105","author":"Tichelli","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.021_bib0043","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ajh.23669","article-title":"Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia","volume":"89","author":"Scheinberg","year":"2014","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.jtct.2025.10.021_bib0044","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/bloodadvances.2024015405","article-title":"Upfront alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice","volume":"9","author":"Bhatt","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.021_bib0045","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","article-title":"How I treat acquired aplastic anemia","volume":"120","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.021_bib0046","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.021_bib0047","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2021012130","article-title":"Long-term outcomes in severe aplastic anemia patients treated with immunosuppression and eltrombopag: a phase 2 study","volume":"139","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.021_bib0048","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/bloodadvances.2021006716","article-title":"Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia","volume":"7","author":"Goronkova","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.jtct.2025.10.021_bib0049","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJM199310143291603","article-title":"Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party","volume":"329","author":"Soci\u00e9","year":"1993","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2025.10.021_bib0050","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.2018874115","article-title":"Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation","volume":"133","author":"Baker","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.021_bib0051","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/bloodadvances.2020003910","article-title":"Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation","volume":"6","author":"Nunez","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.021_bib0052","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaci.2023.05.016","article-title":"Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations","volume":"152","author":"Kunvarjee","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.021_bib0053","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300362","article-title":"Phase 1 study of CK0801 in treatment of bone marrow failure syndromes","volume":"3","author":"Kadia","year":"2024","journal-title":"NEJM Evid"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.021_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28444","volume":"67","author":"Pulsipher","year":"2020","journal-title":"Pediatr Blood Cancer"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:10:24Z","timestamp":1774858224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666636725015246"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}